Canaccord Genuity Maintains Buy on HeartFlow, Raises Price Target to $56
Canaccord Genuity analyst William Plovanic maintains HeartFlow (NASDAQ:HTFL) with a Buy and raises the price target from $45 to $56.
Stocks · News reference
Heartflow FFRCT Analysis Sustains 44% Reduction In Unnecessary Invasive Angiography At One Year, FUSION Trial Confirms
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Software as a Medical Device Market Set for Rapid Growth Through 2034 as AI Innovation, Digital Health Adoption, and Regulatory Advances Reshape the Competitive Landscape
The global Software as a Medical Device (SaMD) market is projected to grow from USD 2.10 billion in 2025 to USD 8.90 billion by 2034, expanding at a CAGR of 17.4%. Growth is driven by AI-enabled diagnostics, digital therapeutics, cloud-based deployment, and maturing regulatory pathways. Diagnostic and screening software leads with 42% market share, while radiology applications dominate at 34%. North America holds 45% of the market, with Asia-Pacific expected to record the fastest growth.
UBS Initiates Coverage On HeartFlow with Neutral Rating, Announces Price Target of $55
Watching Heartflow; Hearing Investor Business Daily SwingTrader Buys Stock